Intravenous Immunoglobulin Dosing for Toxic Epidermal Necrolysis

Evidence for IVIG Dosing in TEN

• High-dose IVIG (total dose of 2-3 g/kg) has been associated with improved survival compared to low-dose IVIG in adults with TEN, according to the British Journal of Dermatology guidelines 1, 2
• Studies using lower doses (0.4 g/kg for 4 days) showed less favorable outcomes with mortality rates of 42%, as reported by the British Journal of Dermatology 3, 4

Duration of Treatment

• The standard duration of IVIG treatment is 3-5 consecutive days, with most successful protocols administering the total dose over 3 days (1 g/kg/day), as recommended by the British Journal of Dermatology guidelines 1, 3, 4

Efficacy Considerations

• The British Journal of Dermatology guidelines note that while some studies show benefit with high-dose IVIG, a meta-analysis found no overall survival benefit compared to supportive care alone (OR 1.00, 95% CI 0.58-1.75) 2, 5, 6
• Pediatric patients treated with IVIG have significantly lower mortality than adults (0% vs. 21.6%), according to the British Journal of Dermatology guidelines 2

Important Caveats

• Despite promising results in some studies, the UK guidelines note that there is no active therapeutic regimen with unequivocal benefit for SJS/TEN, with level 3-4 evidence supporting IVIG use, as reported by the British Journal of Dermatology 1, 2
• High-quality supportive care remains the priority in TEN management regardless of specific interventions, as recommended by the British Journal of Dermatology and other guideline societies 7

Safety Profile

• IVIG may be safer than systemic corticosteroids, which carry concerns about increased infection risk, according to the British Journal of Dermatology guidelines and other medical societies 7

Monitoring During Treatment

• Assess for potential complications including thromboembolic events, renal dysfunction, and aseptic meningitis, as recommended by medical societies 7